Eli Lilly is set to report fourth-quarter earnings early Thursday, with analysts expecting rising sales and profit in the first full quarter with the company's weight-loss drugs no longer in shortage.
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...
Eli Lilly and Co., which cemented its place in ... Here are 71 Mass. life science firms presenting at J.P. Morgan As part of the deal, Scorpion is going to undergo a shakeup.
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter 2024 financial results and 2025 financial guidance on Feb.
Eli Lilly and venture capital firm Andreessen Horowitz ... Lilly Ventures focuses on “opportunities of fun, excellent science,” group vice president of business development for Catalyze360 ...
Lilly India appoints Winselow Tucker as president and general manager: Our Bureau, Mumbai Tuesday, February 4, 2025, 12:15 ...
For nearly a decade, Eli Lilly has been operating a global capability ... including technology engineers and data scientists, the company said in a release. The facility is expected to become ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback